Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lantern Pharma Inc (NQ: LTRN ) 4.650 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 4.650 Bid (Size) 4.570 (1) Ask (Size) 4.900 (1) Prev. Close 4.650 Today's Range 4.650 - 4.650 52wk Range 2.380 - 11.99 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News LTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024 August 08, 2024 LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates August 08, 2024 From Lantern Pharma Inc. Via Business Wire Performance YTD +11.51% +11.51% 1 Month +0.87% +0.87% 3 Month -24.76% -24.76% 6 Month +8.14% +8.14% 1 Year N/A N/A More News Read More Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 August 07, 2024 From Lantern Pharma Via Business Wire Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort August 05, 2024 From Lantern Pharma Via Business Wire Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET August 01, 2024 From Lantern Pharma Inc. Via Business Wire Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 July 10, 2024 From Lantern Pharma Via Business Wire Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 June 12, 2024 From Lantern Pharma Inc. Via Business Wire 12 Health Care Stocks Moving In Monday's After-Market Session May 13, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session May 10, 2024 Via Benzinga LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024 May 09, 2024 Via InvestorPlace Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights May 09, 2024 From Lantern Pharma Inc. Via Business Wire Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism May 06, 2024 From Lantern Pharma Inc. Via Business Wire Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET May 02, 2024 From Lantern Pharma Inc. Via Business Wire 3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire May 01, 2024 Via InvestorPlace Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development April 24, 2024 From Lantern Pharma Inc. Via Business Wire Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan April 22, 2024 From Lantern Pharma Inc. Via Business Wire Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket April 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session April 11, 2024 Via Benzinga Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth April 10, 2024 Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety AI Sector Stalling: Only 4 Of 7 Categories Went Up In March March 31, 2024 Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Six Of Seven AI Stock Categories Increased This Week March 23, 2024 Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 March 20, 2024 Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence 12 Health Care Stocks Moving In Tuesday's Intraday Session March 19, 2024 Via Benzinga LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 March 18, 2024 Via InvestorPlace Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 March 20, 2024 From FN Media Group LLC Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
